NASDAQ:TENX - Tenax Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.23 +0.02 (+1.65 %) (As of 02/15/2019 04:00 PM ET)Previous Close$1.21Today's Range$1.20 - $1.2552-Week Range$1.03 - $12.63Volume184,770 shsAverage Volume614,678 shsMarket Capitalization$1.80 millionP/E RatioN/ADividend YieldN/ABeta1.26 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. Receive TENX News and Ratings via Email Sign-up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TENX Previous Symbol CUSIPN/A Webwww.tenaxthera.com Phone919-855-2100Debt Debt-to-Equity RatioN/A Current Ratio10.08 Quick Ratio10.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.29 per share Price / Book0.20Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,830,000.00 Net MarginsN/A Return on Equity-84.45% Return on Assets-77.21%Miscellaneous Employees7 Outstanding Shares1,465,000Market Cap$1.80 million OptionableNot Optionable Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions What is Tenax Therapeutics' stock symbol? Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX." When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work? Shares of Tenax Therapeutics reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics Inc (NASDAQ:TENX) announced its earnings results on Tuesday, August, 14th. The specialty pharmaceutical company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by $0.29. View Tenax Therapeutics' Earnings History. Has Tenax Therapeutics been receiving favorable news coverage? Media coverage about TENX stock has trended neutral recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tenax Therapeutics earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Tenax Therapeutics' key competitors? Some companies that are related to Tenax Therapeutics include Geovax Labs (GOVX), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY), National Research (NRCIB), National Research (NRCIA), Redpoint Bio (RPBC) and VIRALYTICS Ltd/S (VRACY). Who are Tenax Therapeutics' key executives? Tenax Therapeutics' management team includes the folowing people: Mr. Anthony A. DiTonno, CEO & Director (Age 71)Mr. Michael B. Jebsen, Pres & CFO (Age 48)Mr. John P. Kelley, Consultant (Age 65)Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.Maria Isabel Tomargo, Assistant VP of Marketing & Sales Who are Tenax Therapeutics' major shareholders? Tenax Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (2.59%) and Geode Capital Management LLC (1.89%). View Institutional Ownership Trends for Tenax Therapeutics. Which institutional investors are buying Tenax Therapeutics stock? TENX stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Geode Capital Management LLC. View Insider Buying and Selling for Tenax Therapeutics. How do I buy shares of Tenax Therapeutics? Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tenax Therapeutics' stock price today? One share of TENX stock can currently be purchased for approximately $1.23. How big of a company is Tenax Therapeutics? Tenax Therapeutics has a market capitalization of $1.80 million. Tenax Therapeutics employs 8 workers across the globe. What is Tenax Therapeutics' official website? The official website for Tenax Therapeutics is http://www.tenaxthera.com. How can I contact Tenax Therapeutics? Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected] MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 106 (Vote Outperform)Underperform Votes: 70 (Vote Underperform)Total Votes: 176MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/15/2019 by MarketBeat.com StaffFeatured Article: Is it better to buy a fund with a higher or lower NAV?